Net Income

With two prestigious Stevie® Awards, Dr. Phone Fix validates its model for standardized, reliable service in a fragmented electronics repair market.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Ceva's AI licensing revenue soared in 2025, securing deals with a top PC OEM and Microchip, signaling a major industry shift to on-device intelligence.

Valmont Industries posts strong adjusted Q4 earnings, banking on a booming infrastructure segment to counter a deep agricultural slump and fuel growth in 2026.

Spot's milestone highlights a major trend: as vet costs rise, pet insurance is becoming a crucial financial tool for American families and their pets.

Shutterstock posts record 2025 revenue on AI data growth, but a steep Q4 loss and merger costs reveal deep challenges in its core content business.

A fatal crash and a spike in deaths have prompted a stark warning: the mix of jets, helicopters, and drones in our airspace is a growing global threat.

India's car-sharing leader posts a record quarter, slashing losses by 91% without marketing spend, and now eyes a US market uplisting and new capital.

eToro reports a record $868M in 2025 net contribution and adds $100M to its buyback, betting on AI and its super-app vision despite a Q4 crypto lull.

Tech giant Sony secures access to crucial 5G, Wi-Fi, and video patents, renewing a long-standing agreement with R&D powerhouse InterDigital.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

Warner Bros. Discovery pushes for a Netflix merger but opens a one-week window for Paramount Skydance to fix its flawed bid. A bidding war looms.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

Despite a $70M net loss and falling sales, chemical firm Orion S.A. highlights positive free cash flow and a new focus on financial discipline.

Citing 'prolonged underperformance,' activist investor Starboard Value seeks to replace Tripadvisor's board, igniting a battle for control.

Brunswick Exploration launches a new drill program at a major Quebec lithium find, part of a global strategy in a surging market for critical minerals.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.